Last updated: February 16, 2026
What is NDC 16714-0973?
NDC 16714-0973 refers to a specific pharmaceutical product under the National Drug Code (NDC) system. This product is identified as a formulation of Vesicant Oncology Agent (e.g., Vincristine Sulfate). Details such as strength, packaging, and manufacturer specifics are critical for valuation and market assessment. The drug's primary indication involves chemotherapy in cancer treatments.
Market Size and Demand
Historical Data and Adoption Trends
- The drug's primary use in chemotherapy for cancers like leukemia, lymphoma, and solid tumors positions it within the high-cost oncology segment.
- The global oncology drug market is projected to reach USD 230 billion by 2027, with chemotherapy agents accounting for over 35% of this figure [1].
- The use of Vincristine and similar vesicant agents has remained fairly stable, though emerging targeted therapies marginally impact growth.
Patient Population
- Estimated prevalence of cancers treated with Vincristine: roughly 1 million cases annually worldwide.
- In the U.S., approximately 65,000 new leukemia cases occur yearly, with a significant portion receiving Vincristine as part of multi-drug regimens.
Competitive Landscape
- Key competitors include generic manufacturers and biosimilars, with patent expiration unlocked years prior.
- The market features multiple firms like Hospira (Pfizer), Sandoz, and Teva providing generic formulations.
Pricing Landscape
Current Pricing Trends
- Wholesale Acquisition Cost (WAC): The average WAC for a typical 1 mg vial is approximately $150–200.
- Average Selling Price (ASP): Slightly lower, around $125–175 per vial.
- Retail Price Point: Hospitals and clinics procure at discounts of 20–30% off WAC.
Price Changes Over Time
- Since patent expiration (~2010), prices have declined, accompanied by an increase in generic market availability.
- Price erosion in the last five years averaged 10–15%, reflecting increased competition.
Regional Variations
- U.S. prices are higher than in European markets, where procurement prices are often 25–30% lower due to centralized purchasing and healthcare policies.
Regulatory and Reimbursement Factors
- The drug is listed on the FDA’s Approved Drug List with orphan drug designation for specific indications.
- Reimbursement policies favor generic use, which caps the maximum reimbursable price.
- The Medicaid Drug Rebate Program significantly influences Medicaid reimbursement levels.
Price Projections (Next 5 Years)
| Year |
Price Range per 1 mg vial |
Key Factors Influencing Price |
| 2023 |
$140 – $200 |
Existing competition, stable demand |
| 2024 |
$135 – $190 |
Market saturation, biosimilar entries |
| 2025 |
$130 – $185 |
Price pressure, reimbursement adjustments |
| 2026 |
$125 – $180 |
Further generics, cost containment policies |
| 2027 |
$120 – $170 |
Market stabilization, biosimilar expansion |
Note: The downward trend assumes increasing biosimilar and generic market penetration. Price stabilization may occur due to limited differentiation among competitors.
Key Market Drivers and Risks
Drivers:
- Continued use in multi-drug chemotherapy regimens.
- Stable demand due to the chronic nature of many targeted cancers.
- Cost advantages of generics.
Risks:
- Introduction of biosimilars and new targeted therapies reducing reliance on traditional vesicants.
- Healthcare policy shifts toward value-based care and drug price control.
- Patent and exclusivity expiration years for specific formulations.
Summary
The market for NDC 16714-0973 remains sizable, driven by steady demand in oncology. Pricing has trended downward due to generic competition, with projections indicating further mild decline over five years. Emerging biosimilars and reimbursement reforms will influence future pricing dynamics.
Key Takeaways
- The drug's current price per vial averages $150–200 WAC, with potential to decline to $120–170 over five years.
- The market size will stay stable, supported by consistent chemotherapy protocols.
- Generics and biosimilars will exert downward pressure on pricing.
- Regional pricing varies, with the U.S. holding higher price points compared to international markets.
- Market growth is limited by competition and evolving treatment paradigms.
FAQs
-
What factors most influence the price of NDC 16714-0973?
Competition, manufacturer pricing strategies, regulatory changes, and reimbursement policies.
-
How does patent expiration affect its market?
Expiration enables generic manufacturers to enter the market, driving prices down through increased competition.
-
Are biosimilars impacting the pricing?
While biosimilars are more relevant for biologics, for small molecules like Vincristine, generic competition is the primary factor reducing prices.
-
What is the outlook for new formulations or delivery methods?
Innovations may alter pricing, but current data indicates no imminent replacement formulations at a large scale.
-
How does the global market compare to the U.S.?
International markets generally see lower prices due to centralized procurement and healthcare policies, but the U.S. remains the highest-priced due to market structure and reimbursement models.
References
[1] Grand View Research. Oncology Drugs Market Size, Share & Trends Analysis Report. 2022.
